Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 368-377

  Bumbaca, Daniela ^a   Xiang, Hong ^a   Boswell, C Andrew ^a   Port, Ruediger E ^a   Stainton, Shannon L ^a   Mundo, Eduardo E ^a   Ulufatu, Sheila ^a   Bagri, Anil ^a   Theil, Frank Peter ^a   Fielder, Paul J ^a   Khawli, Leslie A ^a   Shen, Ben Quan ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody; biodistribution; dose escalation; neuropilin 1

Indexed keywords

ANTINEOPLASTIC AGENT; MNRP 1685A; NEUROPILIN 1; PERTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; COMPUTER ASSISTED RADIOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEUROPILIN-1; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84859708396     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01777.x     Document Type: Article

References (41)

1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al,. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727.
2. Adams GP, Weiner LM, (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
3. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al,. (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755.
4. Bagri A, Tessier-Lavigne M, Watts RJ, (2009). Neuropilins in tumor biology. Clin Cancer Res 15: 1860-1864.
5. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK, (1995). Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55: 4611-4622.
6. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M, (2006). Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312: 584-593.
7. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, et al,. (2008). Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 140: 303-312.
8. Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, et al,. (2010). Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm 7: 1848-1857.
9. Boven E, Winograd B, Berger DP, Dumont P, Braakhuis B, Fodstad O, et al,. (1992). Phase II preclinical drug screening in human xenografts: a first European multicenter collaborative study. Cancer Res 52: 5940-5947.
10. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, et al,. (2003). Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9 (10 Pt 1): 3731-3741.
11. Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan JP, et al,. (2011). Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 3: 376-386.
12. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, et al,. (1991). IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol 147: 1548-1556.
13. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al,. (2007). Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67: 254-261.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W, (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
15. Fujimori K, Covell DG, Fletcher JE, Weinstein JN, (1989). Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 49: 5656-5663.
16. Fujimori K, Covell DG, Fletcher JE, Weinstein JN, (1990). A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31: 1191-1198.
17. Haines IE, (2008). Dose selection in phase I studies: why we should always go for the most effective. J Clin Oncol 26: 3650-3652, author reply 3652-3653.
18. Herbst RS, Kim ES, Harari PM, (2001). IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1: 719-732.
19. Jain RK, (1999). Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263.
20. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al,. (2010). Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16: 1289-1297.
21. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al,. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431.
22. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al,. (1993). Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329: 459-465.
23. Kerbel RS, (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2 (4 Suppl. 1): S134-S139.
24. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, et al,. (2006). Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66: 7630-7638.
25. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, et al,. (2007). Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366: 815-829.
26. Lobo ED, Hansen RJ, Balthasar JP, (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668.
27. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, et al,. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56: 455-464.
28. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M, (2002). Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277: 24818-24825.
29. Minchinton AI, Tannock IF, (2006). Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
30. Morgan P, (2001). The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives. Int Congr Ser 1220: 1-12.
31. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al,. (2007). Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53-67.
32. Peterson JK, Houghton PJ, (2004). Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40: 837-844.
33. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al,. (1993). Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219-1224.
34. Rubin EH, Anderson KM, (2010). Finding the right dose for cancer therapeutics-can we do better? Clin Cancer Res 16: 1085-1087.
35. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA, (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (4 Suppl. 12): 60-70.
36. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M, (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
37. Tabrizi M, Bornstein GG, Suria H, (2010). Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12: 33-43.
38. Thurber GM, Schmidt MM, Wittrup KD, (2008). Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29: 57-61.
39. Weekes CD, Hedge P, Xin Y, Yu R, Xiang H, Beeram M, et al,. (2010). A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors (Abstract). 2010 ASCO Annual Meeting, Chicago, IL. J Clin Oncol 28: 15s, 2010 (Suppl.; abstr 3014).
40. Wolf M, Swaisland H, Averbuch S, (2004). Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 10: 4607-4613.
41. de Zafra CLZ, Allamneni K, Kennedy D, Cain G, Xiang H, Auyeung-Kim DL, et al,. (2010). Nonclinical toxicology evaluation of a monoclonal antibody against the VEGF co-receptor neuropilin-1 (Abstract). 49th Annual Meeting of the Society of Toxicology; Salt Lake City, UT. Toxicologist 2010.